Vertex trust sells $4.07 million in shares at $56.48 to $56.52
In a recent filing with the Securities and Exchange Commission, Vertex (NASDAQ:VRTX), Inc. (NASDAQ:VERX) disclosed that the ITEM SECOND IRR. TRUST FBO KYLE R. WESTPHAL, a significant shareholder, ...
2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher
Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...
VRTX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Vertex Pharmaceuticals Incorporated investment
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Vertex Pharmaceuticals' SWOT analysis: stock outlook amid pipeline progress
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to ...
Nasdaq7d
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know
The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96 ... while the tech-heavy Nasdaq depreciated by 0.89%. Coming into today, shares of the drugmaker ...
Nasdaq3d
Validea Detailed Fundamental Analysis - VRTX
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...
Nasdaq13d
Vertex Pharmaceuticals (VRTX) Stock Moves -0.62%: What You Should Know
In the latest market close, Vertex Pharmaceuticals (VRTX) reached $409.56 ... and the technology-dominated Nasdaq saw a decrease of 1.63%. Shares of the drugmaker witnessed a loss of 11.21% ...
Hosted on MSN1d
Vertex Pharmaceuticals (VRTX) Advances But Underperforms Market: Key Facts
Vertex Pharmaceuticals (VRTX) closed at $428 in the latest trading session, marking a +0.03% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.61%. Meanwhile, the ...
Vertex Pharmaceuticals (VRTX) Receives a Hold from RBC Capital
In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research ...
Nasdaq3d
8 Health Care Stocks Whale Activity In Today's Session
Regarding VRTX (NASDAQ:VRTX), we observe a put option trade with bearish sentiment. It expires in 32 day(s) on February 21, 2025. Parties traded 34 contract(s) at a $430.00 strike. The total cost ...
Hosted on MSN22h
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...
Nasdaq12d
VRTX Quantitative Stock Analysis
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...